



Evaluation of Models of Parkinson's Disease

Shail A. Jagmag^{1†}, Naveen Tripathi^{1†}, Sunil D. Shukla², Sankar Maiti¹ and Sukant Khurana^{1*}

¹ Department of Biology, Indian Institute of Science Education and Research, Kolkata, India, ² Department of Zoology, Government Meera Girl's College, Udaipur, India

Parkinson's disease is one of the most common neurodegenerative diseases. Animal models have contributed a large part to our understanding and therapeutics developed for treatment of PD. There are several more exhaustive reviews of literature that provide the initiated insights into the specific models; however a novel synthesis of the basic advantages and disadvantages of different models is much needed. Here we compare both neurotoxin based and genetic models while suggesting some novel avenues in PD modeling. We also highlight the problems faced and promises of all the mammalian models with the hope of providing a framework for comparison of various systems.

OPEN ACCESS

Edited by:

Claudio Soto,
University of Texas, USA

Reviewed by:

Ines Moreno-Gonzalez,
University of Texas, USA
Takahiko Tokuda,
Kyoto Prefectural University of
Medicine, Japan

*Correspondence:

Sukant Khurana
sukantkhurana@gmail.com

[†]These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience

Received: 13 October 2015

Accepted: 21 December 2015

Published: 19 January 2016

Citation:

Jagmag SA, Tripathi N, Shukla SD,
Maiti S and Khurana S (2016)
Evaluation of Models of Parkinson's
Disease. *Front. Neurosci.* 9:503.
doi: 10.3389/fnins.2015.00503

Keywords: Parkinson's Disease, Parkinsonian Disorders, lewy bodies, neurodegeneration, ventral tegmental area (VTA), toxin models, genetic models, substantia nigra pars compacta (SNc)

PARKINSON'S DISEASE—MODEL UTILIZATION FOR THERAPEUTICS

Parkinson's disease (PD) is a common neurodegenerative disorder, with cardinal features of akinesia, bradykinesia, rigidity, and tremors (Rodriguez-Oroz et al., 2009). The neuropathological hallmarks of PD are the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc) and the formation of intra-neuronal proteinaceous inclusions, called Lewy Bodies (LBs). Loss of neurons from other brain regions has also been observed in the later stages of the disease, such as the cholinergic nucleus basalis of Meynert, many subnuclei in the thalamus and amygdala, and the serotonergic neurons of the raphe nucleus (Jellinger, 1991; Braak et al., 2000, 2003). In most cases of PD, injury or environmental insult induced changes in the brain connectivity and gene expression, with genetic factors contributing to the predisposition, are suspected to cause the disease but in a smaller fraction of cases, between 10 and 20%, genes are known to be the culprits for causation. Genetic defects in mitochondrial function (Winklhofer and Haass, 2010), dysfunction of the ubiquitin-proteasome pathway (McNaught et al., 2001), and alterations of free radical formation (Palacino et al., 2004) have been shown to play a role in familial PD. Studies have reported increases in the sensitivity of mice with these defects to neurotoxins (Nieto et al., 2006; Haque et al., 2012).

The use of animals to model different aspects of PD phenotype allows us the ability to study both disease progression and explore possible treatments. While none of the currently available models of PD completely phenocopy the disease but they have contributed extensively to our knowledge of PD. So far experimental models have been of two major types: (A) Toxin models and (B) Genetic models. An understanding of different PD models can enhance the ability of PD researcher to employ appropriate models for their experiments.


TOXIN BASED MODELS

These are based on neurotoxins which allow for testing of nigrostriatal DA neuron degeneration. **Figure 1** summarizes major toxin models.

6-OHDA

6-hydroxydopamine (6-OHDA), presented in **Figure 1A**, is a selective neurotoxin that was first reported to cause lesions in nigrostriatal DA neurons in rats (Ungerstedt, 1968) but has been subsequently shown to work in other animals such as mice (da

Conceição et al., 2010; Thiele et al., 2012). 6-OHDA accumulates in the cytosol and promotes formation of hydrogen peroxide, other reactive oxygen species and quinines by auto-oxidation (Cohen, 1984; Simola et al., 2007). Down regulation of dopamine synthesis in the lesioned striatum has also been observed with the non-lesioned striatum compensating for this by increased dopamine production (Del-Bel et al., 2014) 6-OHDA being hydrophilic cannot cross the blood brain barrier and thus administration is carried out by direct injection in the Substantia Nigra pars Compacta (SNc), Medial Forebrain Bundle (MFB) or striatum, depending on the rate at which lesion formation is desired. Injection into the SNc, MFB causes DA neuronal death in



less than 24 h (Jeon et al., 1995). Striatal injection causes death of DA neurons over the course of 1–3 weeks. Injection of 6-OHDA causes progressive retrograde neuronal degeneration in the SNc and Ventral Tegmental Area (VTA) (Sauer and Oertel, 1994; Przedborski et al., 1995). In addition to DA transporters, it also targets noradrenergic transporters (Luthman et al., 1989). Thus, in addition to inducing PD symptoms, 6-OHDA also causes damage to other parts of the brain. The other disadvantage of 6-OHDA is that production of LB-like inclusions is not seen (Dauer and Przedborski, 2003). Behavioral wise, unilaterally lesioned rodents show drug induced rotational behavior (Blandini et al., 2008). Motor impairments are also observed, primarily due to impairment of limbs contralateral to the hemisphere in which the 6-OHDA is administered (Simola et al., 2007).

MPTP

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), presented in **Figure 1B**, is a neurotoxin precursor of 1-methyl-4-phenylpyridinium (MPP⁺), which causes damage to the nigrostriatal DA pathway with a significant loss of DA neurons in the striatum and SNc, more similar to that seen in PD. MPTP susceptibility increases with age (Ovadia et al., 1995). MPTP is converted to an intermediate 1-methyl-4-phenyl-2,3-dihydropyridinium by the action of monoamine oxidase B in glial cells. This intermediate is then oxidized to MPP⁺ (Jackson-Lewis and Przedborski, 2007). MPP⁺ has a high affinity for the plasma membrane dopamine transporter with comparatively lower affinities for the norepinephrine and serotonin transporters (Javitch et al., 1985). Once inside dopaminergic neurons, MPP⁺ can be sequestered into synaptosomal vesicles or be concentrated within the mitochondria (Ramsay and Singer, 1986) utilizing mitochondrial transmembrane potential. In the mitochondria, MPP⁺ blocks the electron transport chain by inhibiting Mitochondrial Complex I (Varastet et al., 1994). Due to rapid conversion of MPTP to MPP⁺, most chronic treatments are actually serial acute insults (Jackson-Lewis and Przedborski, 2007). Thus, a true chronic model would require continuous delivery of MPTP using devices such as osmotic pumps (Fornai et al., 2005). Rats have proven to be resistant to MPTP induced toxicity (Riachi et al., 1990). The reason for this resistance has been speculated to be because of differential MPP⁺ sequestration (Schmidt and Ferger, 2001). While MPTP produces the best results when used in monkeys including formation of LB like inclusions (Kowall et al., 2000) taking into account practical considerations, the MPTP mouse model is more popular. MPTP causes greater damage to DA neurons in the SNc than in VTA (Blesa et al., 2011, 2012). Recent dopaminergic neuron characterisation has found a specific DA subtype in the SNc is more vulnerable to MPTP (Poulin et al., 2014). Also the degeneration of nerve terminals to the putamen is higher than those to the caudate nucleus (Blesa et al., 2010). This too resembles PD phenotype.

Mice treated with MPTP also do not show behavior typical of PD, however alterations in motor movement are observed, where significant dopaminergic neuron loss is present (Jackson-Lewis and Przedborski, 2007). This model also has a significant

weakness of the lack of formation of LBs in mice. Care must be taken to study the interaction of the drug tested with MPP⁺ before conclusions about its efficacy are drawn as some drugs might reduce the oxidative stress induced by MPTP. Also the conversion of MPTP to MPP⁺ includes an intermediate, which is oxidized to MPP⁺, thus an antioxidant treatment protocol might give good results by targeting this step without actually preventing DA neuron loss but this remains to be tested. Use of probenidol to competitively inhibit renal excretion of MPTP has also been shown to increase SNc neuronal loss (Meredith et al., 2002). MPTP has a big advantage because of its lipophilic nature as it can cross the blood brain barrier, thus allowing greater ease in administration, including systemic administration.

ROTENONE

Rotenone, presented in **Figure 1C**, occurs naturally in several plants and has been used as a broad spectrum insecticide, and pesticide. It functions by blocking the mitochondrial electron transport chain through inhibition of complex I, as seen in MPTP. Rotenone also blocks mitosis and inhibits cell proliferation. This is by perturbation of microtubule assembly and decreasing the GTP hydrolysis rate (Srivastava and Panda, 2007). Chronic systemic exposure to rotenone in rats causes many features of PD, including nigrostriatal DA degeneration. This model has been shown to reproduce almost all the features of PD, including the formation of intracellular inclusions that resemble LB (Sherer et al., 2003). Rotenone can be injected intraperitoneally, intravenously or subcutaneously for systemic treatment. It has also been directly injected into the brain stereotactically (Xiong et al., 2009). However, despite demonstrating the slow and specific loss of DA neurons, this model is difficult to replicate due to the high mortality observed in rats, when treated with rotenone (Fleming et al., 2004). Rotenone is highly lipophilic and easily crosses the blood brain barrier (Talpadé et al., 2000).

PARAQUAT

N,N'-dimethyl-4,4'-bipyridinium dichloride (Paraquat), presented in **Figure 1D**, is one of the most widely used herbicides. It shares structural similarity to MPP⁺. Paraquat causes oxidative stress in the cell through generation of reactive oxygen species. It has been shown to cause SNc DA neuron degeneration and like rotenone also induces formation of LB in DA neurons in mice and rats (McCormack et al., 2002; Cicchetti et al., 2005). However, large variability has been observed in cell death and specificity for DA neurons including some contradictions, with some researchers claiming that Paraquat does not cause changes in the nigrostriatal DA system (Miller, 2007). Paraquat has been used in conjunction with 2-(dithiocarboxy)aminoethylcarbamidithioato(2-)-kS, kS' manganese also called Maneb, a fungicide, which has been shown to potentiate the effects of both MPTP and Paraquat. Maneb on its own has also been shown to decrease locomotor activity and produce SNc neurons loss (Thrash et al., 2007).

AMPHETAMINE BASED MODELS

Treatment of rodents and primates with high doses of methamphetamine has shown selective DA, serotonergic nerve terminal as well as SNc neuronal loss (Wagner et al., 1979; Thrash et al., 2009). Methamphetamine, presented in **Figure 1E**, causes this damage by promoting change in the distribution of DA from the synaptic vesicle to the cytosol (Howard et al., 2011). To do so, it interacts with both the dopamine transporter (DAT) and the vesicular monoamine transporter (VMAT2), resulting in promoting the collapse of vesicular proton gradients. This leads to DA oxidation within the neuronal cytosol, which causes oxidative stress within the cell by generation of hydroxyl and superoxide Reactive Oxygen Species (ROS) (Larsen et al., 2002; Cadet et al., 2007). Subtoxic concentrations of methamphetamine has been shown to protect DA neurons cells against 6-OHDA toxicity, whereas higher concentrations of methamphetamine exacerbated it (El Ayadi and Zigmond, 2011). On the other hand, despite affecting mainly the serotonergic system, MDMA can also affect DA neurons, with the repeated administration of MDMA producing degeneration of DA terminals in the striatum, and neuronal loss in the SNc (Granado et al., 2008a,b). Development of an amphetamine model of PD, especially in conjunction with other neurotoxins such as MPTP, and Paraquat might be useful.

GENETIC MODELS

In theory genetic model of a simple disease or a syndrome can be made of a mutant gene involved in the progression of the disease in patients or even a gene that might not be validated to be involved in patients but can recapitulate some key features of the disease in the model system. The goal of making genetic model is 3-fold:

1. Understand the signaling and pathways associated with known causal gene.
2. Understand disease signaling by introducing a perturbation in signaling through a gene not found to be causal in patients but can mimic key disease and equally importantly disease like phenotypes.
3. To enable therapeutic screens.

Five genes are frequently targeted as disease models for PD and they have all been known to have causal connection in familial PD. One of the largest genome wide analysis studies for PD to date has implicated 28 independent variants across 24 loci (Nalls et al., 2014). What is not obvious is whether the genes encoded (Nalls et al., 2014) within these loci function as the main drivers, carriers or helpers of disease progression. In more common forms of PD, several gene functions are likely to be altered, hence monogenic models are expected to be less successful than toxin-induced models. That said genetic models have been of use in modeling familial PD and also have shed some light on more common PD mechanisms. Some of the model organisms have been invertebrates and one might be led to question the utility of invertebrate models that do not have SNc. While invertebrate models mimic more simplistic features such

as loss of DA neurons, they provide a good vehicle to understand the genetic network, molecular signaling, and provide for first round of screening that can be followed up with further work in mammalian models. **Tables 1–4** describe the various common rodent genetic models for PD, while **Table 5** details fruit fly models. Some of the models are described below:

α -SYNUCLEIN

This gene is linked to a dominant type of familial PD and the α -synuclein protein is a major part of LBs observed in the brains of PD patients (Iwatsubo, 2003). **Table 1** catalogs α -synuclein mice models, while **Table 4** has rat genetic models, including α -synuclein. Mutations in five locations have so far been identified in familial PD (Polymeropoulos et al., 1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz et al., 2004; Appel-Cresswell et al., 2013; Kiely et al., 2013; Proukakis et al., 2013). Injection of wild type or mutant α -synuclein protein has been shown to induce loss of DA neurons, and cause motor impairment in both mice and rats (Oliveras-Salvá et al., 2013). Several mutant lines have been developed in mice that show decreases in striatal DA, exhibit inclusion bodies, and show motor impairments but several fail to show significant degeneration of nigrostriatal PD neurons (Masliah, 2000; van der Putten et al., 2000; Giasson et al., 2002; Lee et al., 2002; Richfield et al., 2002; Gomez-Isla et al., 2003; Fernagut and Chesselet, 2004; Thiruchelvam et al., 2004; Tofaris et al., 2006; St Martin et al., 2007; Nuber et al., 2008; Wakamatsu et al., 2008; Daher et al., 2009). Recent use of the Pitx3 promoter shows promise as the line shows progressive SNc DA neuronal loss too along with decrease in DA release and significant motor defects (Li et al., 2009a; Lin et al., 2012). Viral Vectors such as Lentiviruses, Adeno-associated Viruses have been directly injected into the brain at the SNc near the cell bodies of DA neurons in both mice and rats (Lauwers et al., 2003, 2007). Mutant lines with DA loss and inclusion bodies have also been developed in rats (Klein et al., 2002; Lo Bianco et al., 2002; Yamada et al., 2004; McFarland et al., 2009; Koprich et al., 2010; Oueslati et al., 2012; Engeln et al., 2013). While so many models have been developed with α -synuclein, its exact function is not known. Available data suggests that α -synuclein might be a presynaptic regulator of DA release, synthesis or storage, and has been shown to be a regulator of paired-stimulus depression (PSD) (Maries et al., 2003). It also seems to play a role in neuroprotection (Quilty et al., 2006).

LRRK 2

Mutations to this gene are known to cause an autosomal familial form of PD (Funayama et al., 2002; Paisán-Ruiz et al., 2004). Mice LRRK2 lines are compared in **Table 2** and rat lines in **Table 4**. Mitochondrial dysfunction enhances LRRK2 neurodegeneration in some models through unclear mechanisms (Winklhofer and Haass, 2010). LRRK 2 knockout mice have been demonstrated to show abnormal aggregation and accumulation of proteins including α -synuclein, while otherwise not showing any nigrostriatal degeneration (Li et al., 2007, 2009b; Melrose

TABLE 1 | α -synuclein models in mice.

α -synuclein in mouse model					
Types	Promoter	SN neuron loss	Inclusion bodies	Motor impairment	References
WT	PDGF- β	–	+	+	Masliyah, 2000
WT/A53T	Thy1	–	+	+	van der Putten et al., 2000
WT/A30P/A53T	TH	–	–	ND	Matsuoka et al., 2001
WT	Prp	–	–	–	Giasson et al., 2002
A53T	Prp	–	+	+	Giasson et al., 2002
WT	Prp	–	–	–	Lee et al., 2002
A30P	Prp	–	+	–	Lee et al., 2002
A53T	Prp	–	+	+	Lee et al., 2002
WT	TH	–	–	–	Richfield et al., 2002
A53T and A30P	TH	+	–	+	Thiruchelvam et al., 2004
A30P	PrP	–	+	+	Gomez-Isla et al., 2003
WT/A30P/A53T	CMV	+	+	+	Lauwers et al., 2003
WT (1–120)	TH	–	+	+	Tofaris et al., 2006
WT	CMV	+	–	ND	St Martin et al., 2007
WT	CaMKII	+	–	+	Nuber et al., 2008
WT (1–130)	TH	+	–	+	Wakamatsu et al., 2008
WT (1–119)	ROSA26	–	–	ND	Daher et al., 2009
A53T	ROSA26	–	–	ND	Daher et al., 2009
E46K	ROSA26	–	–	ND	Daher et al., 2009
A53T	Pitx3	+	–	+	Lin et al., 2012
WT/A53T	CMVE- Syn 1	+	+	+	Oliveras-Salvá et al., 2013

WT, Human α -synuclein; PDGF- β , Platelet Derived Growth Factor- β ; Thy-1, Thy-1 Cell Surface Antigen; TH, Tyrosine Hydroxylase; Prp, Prion protein promoter; CMV, cytomegalovirus; CaMKII, Calcium/calmodulin-dependent protein kinase II; ROSA26, ROSA β geo26P locus; Pitx3, Paired-Like Homeodomain 3; CMVE- Syn 1, cytomegalovirus enhanced synapsin 1; ND, No Data.

TABLE 2 | LRRK2 models in mice.

LRRK2 in mouse model					
Types	Promoter	SN neuron loss	Inclusion bodies	Motor impairment	References
R1441C/G*	mLRRK2	ND	ND	ND	Li et al., 2007
R1441C*	mLRRK2	–	–	–	Tong et al., 2009
WT [#]	mLRRK2	–	–	+	Li et al., 2009b
R1441G [#]	mLRRK2	–	–	+	Li et al., 2009b
WT [#]	hLRRK2	–	–	–	Melrose et al., 2010
G2019S [#]	hLRRK2	–	–	–	Melrose et al., 2010
exon 1*	mLRRK2	–	+	ND	Tong et al., 2010
exon 29, 30*	mLRRK2	–	+	ND	Tong et al., 2010
G2019S [#]	CMVE- PDGF β	+ (DA loss)	–	–	Ramonet et al., 2011
R1441C [#]	CMVE-PDGF β	–	–	+	Ramonet et al., 2011
WT [#]	CMVE-PDGF β	–	–	–	Ramonet et al., 2011
G2019S [#]	CMVE-PDGF β	+ (DA loss)	–	+	Chen et al., 2012
R1441C [#]	ROSA26	–	–	–	Tsika et al., 2014

mLRRK2, murine LRRK2; hLRRK2, human LRRK2; *mouse paralog, [#]human; WT, Wild Type; CMVE-PDGF β , cytomegalovirus enhanced-platelet derived growth factor- β ; ROSA26, ROSA β geo26P locus; ND, No Data.

et al., 2010; Tong et al., 2010; Ramonet et al., 2011; Hinkle et al., 2012; Tsika et al., 2014). Virus based models have so far shown some nigrostriatal degeneration however only partial

PD phenotypes have so far been developed (Dusonchet et al., 2011; Chen et al., 2012). The LRRK2 gene codes for a 2527 amino acid long protein with multiple domains (Anand and

TABLE 3 | Parkin, PINK1, and DJ-1 mice models.

Mouse model					
	Promoter	SN neuron loss	Inclusion bodies	Motor impairment	References
PARKIN MOUSE PARALOG					
Exon 3 deletion	—	—	—	—	Goldberg et al., 2003
Exon 3 deletion	—	—	—	+	Itier et al., 2003
Exon 2 deletion	—	—	—	—	Perez and Hastings, 2004
Exon 7 deletion	—	—	—	—	Von Coelln et al., 2004
Exon 3 deletion	—	ND	ND	ND	Palacino et al., 2004
Truncated, Q311X	<i>Slc6a3</i>	+ (DA loss)	—	+	Lu et al., 2009
WT	nse	—	ND	ND	Bian et al., 2012
PINK-1 MOUSE PARALOG					
4–7 Exon mutation	—	—	—	—	Kitada et al., 2007
DJ-1 MOUSE PARALOG					
Exon 2 deletion	—	—	—	+	Goldberg et al., 2005,
Exon 2 deletion	—	—	ND	ND	Yamaguchi and Shen, 2007,
Exon 3–5 deletion	—	—	ND	—	Kim et al., 2005
Exon 7 inactivation	—	—	ND	+	Manning-Boğ et al., 2007
Exon 2–3 deletion	—	—	ND	—	Andres-Mateos et al., 2007
Exon 2 deletion	—	—	—	+	Chandran et al., 2008
Exon 1 stop	—	+	ND	—	Rousseaux et al., 2012

WT, Wild Type; *Slc6a3*, Solute carrier family 6a3; *nse*, neuron specific enolase; ND, No Data.

Braithwaite, 2009). Of these domains, two enzymatic domains, the kinase domain and the GTPase domain are of particular interest. In addition multiple protein-protein interaction regions suggest that LRRK may have a role as a major signaling complex (Marín, 2006; Mata et al., 2006). More information on LRRK 2 interactions is needed.

PARKIN

Parkin mutations have been seen in cases of familial PD. **Table 3** covers Parkin mice strains. Parkin is an integral ligase in the ubiquitin proteasome system (Lücking et al., 2000). Most Parkin transgenic rodents do not exhibit loss of DA neurons in the SNc (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004; Von Coelln et al., 2004; Perez and Palmiter, 2005; Lu et al., 2009; Bian et al., 2012; Liu et al., 2013). Some recent transgenic rodent models have demonstrated modest loss of DA neurons (Kitada et al., 2009; Dave et al., 2014; Van Rompuy et al., 2014). Popular adoption of these models awaits successful reproduction of the results.

DJ-1

DJ-1 is molecular chaperone that under redox reductions plays a role in inhibition of α -synuclein aggregate formation (Shendelman et al., 2004). DJ-1 mutations are linked to autosomal recessive, early onset PD and genetic models using DJ-1 are cataloged in **Table 3**. Rat model of DJ-1 is presented in **Table 4**. KO models of DJ-1 show decreased DA release in the striatum but no loss of SNc DA neurons (Goldberg et al., 2005; Andres-Mateos et al., 2007; Manning-Boğ et al., 2007; Yamaguchi

and Shen, 2007; Chandran et al., 2008). Hypersensitivity to neurotoxins, such as MPTP, was also observed in DJ-1 deficient mice (Kim et al., 2005). One new model, the DJ1-C57 mouse, shows promise with dramatic unilateral loss of dopaminergic (DA) neurons in the SNc that progresses to bilateral degeneration of the nigrostriatal axis with aging and mild motor behavior deficits (Rousseaux et al., 2012). If reproduced, this model would be highly beneficial to study early onset PD. A transgenic rat model of DJ-1 has also been produced, which exhibits dopaminergic neuron loss and motor abnormalities (Dave et al., 2014).

PINK1

Mutations in the PARK6 locus of PINK1 cause a form of early-onset autosomal PD. **Table 3** presents mice model of PINK1 and **Table 4** rat models. PINK1 codes for a mitochondrial kinase, which recruits Parkin from the cytosol to the mitochondria, increases the ubiquitination activity of Parkin, and induces Parkin-mediated mitophagy (Lazarou et al., 2013). Since PINK1 and the Parkin function in the same pathway, the phenotypes of PINK1 and Parkin KO mice are very similar. No significant DA neuron abnormalities or LB formation have been observed in PINK1 KO mice however mitochondrial functional defects and increased sensitivity to oxidative stress were observed (Kim et al., 2005; Kitada et al., 2007). Increased levels of α -synuclein through overexpression in PINK1 KO mice results in DA loss but no degeneration in the SNc (Oliveras-Salvá et al., 2013). PINK1 KO rats exhibiting DA loss and motor impairment have been developed recently which more closely mimics PD phenotype (Dave et al., 2014).

TABLE 4 | Genetic models in rats.

Rat model					
Types	Promoter	SN neuron loss	Inclusion bodies	Motor impairment	References
HUMAN α-SYNUCLEIN					
A30P	BA	+ (DA loss)	+	ND	Klein et al., 2002
WT	CBA	+	+	+	Kirik et al., 2002
A53T	CBA	+	+	+	Kirik et al., 2002
WT/A30P/A53T	PGK	+ (DA loss)	+	ND	Lo Bianco et al., 2002
WT	CMV	+ (DA loss)	–	ND	Yamada et al., 2004
WT, S129D, S129A	CMV	+ (DA loss)	+	ND	McFarland et al., 2009
A53T	CBA	+ (DA loss)	+	ND	Koprach et al., 2010
WT, S87A	ND	+ (DA loss)	+	+	Oueslati et al., 2012
S87E	ND	–	+	–	Oueslati et al., 2012
WT	SYN 1	+ (DA loss)	+	+	Engeln et al., 2013
HUMAN LRRK2					
WT	SYN 1	–	–	ND	Dusonchet et al., 2011
G2019S	SYN 1	+	–	ND	Dusonchet et al., 2011
PARKIN RAT HOMOLOG					
WT	PGK	–	ND	ND	Liu et al., 2013
WT (KO -Exon 4)	–	–	–	–	Dave et al., 2014
DJ-1 RAT HOMOLOG					
WT (KO -Exon 5)	–	+ (DA loss)	–	+	Dave et al., 2014
PINK-1 RAT HOMOLOG					
WT (KO -Exon 4)	–	+ (DA loss)	–	+	Dave et al., 2014

WT, Wild -Type; BA, beta actin; CBA, chicken beta actin; PGK, phosphoglycerate kinase; CMV, cytomegalovirus; SYN-1, synapsin I; ND, No Data.

NON-MAMMALIAN GENETIC MODELS OF PD

Barring α -synuclein, most familial PD genes have at least one drosophila homolog. This includes homologs of PINK1, Parkin, DJ-1, and LRRK2 that have been presented in **Table 5**. Models with human α -synuclein and LRRK2 have also been developed (Feany and Bender, 2000; Auluck et al., 2002; Chen and Feany, 2005; Pesah et al., 2005; Periquet et al., 2007; Liu et al., 2008; Ng et al., 2009). These transgenic flies show some of the traits of familial PD, with well characterized loss of dopaminergic neurons and motor impairment, except in the case of DJ-1 in which only motor impairment has been observed in DJ-1 β partial deletion (Greene et al., 2003; Pesah et al., 2004; Chen and Feany, 2005; Meulener et al., 2005; Park et al., 2005, 2006; Clark et al., 2006; Lavara-Culebras and Paricio, 2007; Sang et al., 2007). *D. melanogaster* transgenic models have also helped in elucidating the role of DJ-1, Parkin and PINK1 in mitochondrial physiology (Venderova et al., 2009; Cookson, 2012). Further the study of interactions of human α -synuclein, LRRK2, Parkin, PINK1, and DJ-1 genes has also been possible in the drosophila system (Hirth, 2010).

Like *D. melanogaster*, *D. rerio* homologs of most familial PD genes have been discovered. Unlike the rodent and drosophila genetic models of PD, comparatively less characterisation has been carried out in *D. rerio*. Expression of human α -synuclein and knockouts of Parkin, PINK1, DJ-1 and LRRK2 have been generated, which show some success in mimicking symptoms of

familial PD (Park et al., 2006; Bretau et al., 2007; Anichtchik et al., 2008; Flinn et al., 2009; Fett et al., 2010; Sheng et al., 2010; Milanese et al., 2012; Priyadarshini et al., 2013; O'Donnell et al., 2014). Verification of the results and further behavioral testing is required to establish these models for therapeutic screens.

The advantages of transparency and complete cell lineage information make *C. elegans* an interesting model for neurodegenerative diseases. Homologs of human PD-related proteins, including Parkin, LRRK2, PINK1 and DJ-1, have been found in *C. elegans* (Springer et al., 2005; Sakaguchi-Nakashima et al., 2007; Sämann et al., 2009; Kamp et al., 2010; Lee et al., 2013; Chen et al., 2015). Transgenic models developed for these genes have shown increase sensitivity to neurotoxins like MPTP (Ved et al., 2005).

CONCLUSION

Both toxin and genetic based models have their advantages and disadvantages. However, the use of the two in combination would be quite beneficial. Thus, a multi gene modulated transgenic model in combination with a reliable and effective neurotoxin might allow us to model the PD phenotype better. Addition of a miRNA or siRNA cocktail to the appropriate model systems could potentially allow for the creation of a very robust and accurate PD model showing all the symptoms of PD. Development of primary cell culture models might allow for mimicking slow development of PD cellular damage phenotype

TABLE 5 | Genetic models in fruit flies.

Drosophila model					
Types	Driver	DA neuron loss	Inclusion bodies	Motor impairment	References
Human α-synuclein					
WT/A30P/A53T	elav-GAL 4	+	+	+	Feany and Bender, 2000
WT/A30P/A53T	elav-GAL 4	+	+	ND	Auluck et al., 2002
WT	elav-GAL 4	–	+	+	Pesah et al., 2005
S129D	elav-GAL 4	+	+	ND	Chen and Feany, 2005
S129A	elav-GAL 4	–	+	ND	Chen and Feany, 2005
WT 71–82 removed	elav-GAL 4	–	–	ND	Periquet et al., 2007
WT 1–120 trunc.	elav-GAL 4	+	+	ND	Periquet et al., 2007
WT 1–78 trunc.	elav-GAL 4	+	+	ND	Periquet et al., 2007
Human LRRK2					
WT	elav-GAL 4	+	ND	+	Liu et al., 2008
G2019S	elav-GAL 4	+	ND	+	Liu et al., 2008
I2020T	elav-GAL 4	–	–	+	Venderova et al., 2009
WT	ddc-GAL4	–	–	–	Ng et al., 2009
G2019S	ddc-GAL4	+	–	+	Ng et al., 2009
Y1699C	ddc-GAL4	+	–	+	Ng et al., 2009
G2385R	ddc-GAL4	+	–	–	Ng et al., 2009
PARKIN FLY HOMOLOG					
p25 insertion (null)	–	–	ND	+	Greene et al., 2003
P21 insertion (null)	–	–	–	+	Pesah et al., 2004
Q311X/T240R	ddc-GAL4	+	–	+	Sang et al., 2007
DJ-1 FLY HOMOLOG					
DJ-1 β part deletion	–	–	–	+	Park et al., 2005
DJ-1 α null	–	–	–	ND	Meulener et al., 2005
DJ-1 β null	–	–	–	ND	Meulener et al., 2005
DJ-1 β null	–	–	ND	ND	Menzies et al., 2005
DJ-1 α RNAi	–	+	ND	–	Lavara-Culebras and Paricio, 2007
DJ-1 β null	–	–	ND	–	Lavara-Culebras and Paricio, 2007
PINK-1 FLY HOMOLOG					
Kinase domain	–	–	ND	+	Clark et al., 2006
UTR + part of exon 1	–	+	ND	+	Park et al., 2006

WT, Wild-type; elav, Embryonic Lethal—Abnormal Vision; ddc, dopa decarboxylase; RNAi, RNA Interference; UTR, Untranslated Region; ND, No Data.

too, and be useful for drug discovery. In coming years, we expect to see better models for both basic understanding of PD and also for improved high-throughput drug-discovery.

AUTHOR CONTRIBUTIONS

SJ conducted overall review of the field and wrote major part of this manuscript. NT co-conducted the review of the field. SS and

SM provided expertise on selected topics, wrote and edited select parts of the manuscript. SK envisaged the overall study, guided the work of SJ and NT, and conducted the final editing.

FUNDING

SJ was funded by CSIR Ph.D. fellowship. SK's lab is funded by intramural IISER-K funding.

REFERENCES

- Anand, V. S., and Braithwaite, S. P. (2009). LRRK2 in Parkinson's disease: biochemical functions. *FEBS J.* 276, 6428–6435. doi: 10.1111/j.1742-4658.2009.07341.x
- Andres-Mateos, E., Perier, C., Zhang, L., Blanchard-Fillion, B., Greco, T. M., Thomas, B., et al. (2007). DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. *Proc. Natl. Acad. Sci. U.S.A.* 104, 14807–14812. doi: 10.1073/pnas.0703219104
- Anichtchik, O., Diekmann, H., Fleming, A., Roach, A., Goldsmith, P., and Rubinsztein, D. C. (2008). Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. *J. Neurosci.* 28, 8199–8207. doi: 10.1523/JNEUROSCI.0979-08.2008
- Appel-Cresswell, S., Vilarino-Guelli, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Mov. Disord.* 28, 811–813. doi: 10.1002/mds.25421
- Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M. Y., and Bonini, N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a *Drosophila* model for Parkinson's disease. *Science* 295, 865–868. doi: 10.1126/science.1067389
- Bian, M., Liu, J., Hong, X., Yu, M., Huang, Y., Sheng, Z., et al. (2012). Overexpression of Parkin Ameliorates Dopaminergic Neurodegeneration Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice. *PLoS ONE* 7:e39953. doi: 10.1371/journal.pone.0039953
- Blandini, F., Armentero, M.-T., and Martignoni, E. (2008). The 6-hydroxydopamine model: news from the past. *Parkinsonism Relat. Disord.* 14 (Suppl. 2), S124–S129. doi: 10.1016/j.parkreldis.2008.04.015
- Blesa, J., Juri, C., Collantes, M., Peñuelas, I., Prieto, E., Iglesias, E., et al. (2010). Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study. *Neurobiol. Dis.* 38, 456–463. doi: 10.1016/j.nbd.2010.03.006
- Blesa, J., Juri, C., García-Cabezas, M. Á., Adán, R., Sánchez-González, M. Á., Cava, C., et al. (2011). Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. *Front. Syst. Neurosci.* 5:92. doi: 10.3389/fnsys.2011.00092
- Blesa, J., Pif, C., Sánchez-González, M. Á., Juri, C., García-Cabezas, M. Á., Adán, R., et al. (2012). The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. *Neurobiol. Dis.* 48, 79–91. doi: 10.1016/j.nbd.2012.05.018
- Braak, H., Rüb, U., Sandmann-Keil, D., Gai, W. P., de Vos, R. A., Jansen Steur, E. N., et al. (2000). Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. *Acta Neuropathol.* 99, 489–495. doi: 10.1007/s004010051150
- Braak, H., Del Tredici K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9
- Breitaud, S., Allen, C., Ingham, P. W., and Bandmann, O. (2007). p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. *J. Neurochem.* 100, 1626–1635. doi: 10.1111/j.1471-4159.2006.04291.x
- Cadet, J. L., Krasnova, I. N., Jayanthi, S., and Lyles, J. (2007). Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. *Neurotox. Res.* 11, 183–202. doi: 10.1007/BF03033567
- Chandran, J. S., Lin, X., Zapata, A., Höke, A., Shimoji, M., Moore, S. O., et al. (2008). Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. *Neurobiol. Dis.* 29, 505–514. doi: 10.1016/j.nbd.2007.11.011
- Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet (London, England)* 364, 1167–1169. doi: 10.1016/S0140-6736(04)17103-1
- Chen, C.-Y., Weng, Y.-H., Chien, K.-Y., Lin, K.-J., Yeh, T.-H., Cheng, Y.-P., et al. (2012). (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. *Cell Death Differ.* 19, 1623–1633. doi: 10.1038/cdd.2012.42
- Chen, L., and Feany, M. B. (2005). Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a *Drosophila* model of Parkinson disease. *Nat. Neurosci.* 8, 657–663. doi: 10.1038/nn1443
- Chen, P., DeWitt, M. R., Bornhorst, J., Soares, F. A., Mukhopadhyay, S., Bowman, A. B., et al. (2015). Age- and manganese-dependent modulation of dopaminergic phenotypes in a *C. elegans* DJ-1 genetic model of Parkinson's disease. *Metallomics* 7, 289–98. doi: 10.1039/C4MT00292J
- Cicchetti, F., Lapointe, N., Roberge-Tremblay, A., Saint-Pierre, M., Jimenez, L., Ficke, B. W., et al. (2005). Systemic exposure to paraquat and Maneb models early Parkinson's disease in young adult rats. *Neurobiol. Dis.* 20, 360–371. doi: 10.1016/j.nbd.2005.03.018
- Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., et al. (2006). *Drosophila* pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* 441, 1162–1166. doi: 10.1038/nature04779
- Cohen, G. (1984). Oxy-radical toxicity in catecholamine neurons. *Neurotoxicology* 5, 77–82.
- Cookson, M. R. (2012). Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. *Cold Spring Harb. Perspect. Med.* 2:a009415. doi: 10.1101/cshperspect.a009415
- da Conceição, F. S., Ngo-Abdalla, S., Houzel, J. C., and Rehen, S. K. (2010). Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test. *J. Vis. Exp.* 35:1376. doi: 10.3791/1376
- Daher, J. P. L., Ying, M., Banerjee, R., McDonald, R. S., Hahn, M. D., Yang, L., et al. (2009). Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. *Mol. Neurodegener.* 4:34. doi: 10.1186/1750-1326-4-34
- Dauer, W., and Przedborski, S. (2003). Parkinson's Disease. *Neuron* 39, 889–909. doi: 10.1016/S0896-6273(03)00568-3
- Dave, K. D., De Silva, S., Sheth, N. P., Ramboz, S., Beck, M. J., Quang, C., et al. (2014). Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. *Neurobiol. Dis.* 70, 190–203. doi: 10.1016/j.nbd.2014.06.009
- Del-Bel, E., Padovan-Neto, F. E., Szawka, R. E., da-Silva, C. A., Raisman-Vozari, R., Anselmo-Franci, J., et al. (2014). Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment. *Neurotox. Res.* 25, 33–44. doi: 10.1007/s12640-013-9406-3
- Dusonchet, J., Kochubey, O., Stafa, K., Young, S. M., Zufferey, R., Moore, D. J., et al. (2011). A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. *J. Neurosci.* 31, 907–912. doi: 10.1523/JNEUROSCI.5092-10.2011
- El Ayadi, A., and Zigmond, M. J. (2011). Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study. *PLoS ONE* 6:e24722. doi: 10.1371/journal.pone.0024722
- Engel, M., Fasano, S., Ahmed, S. H., Cador, M., Baekelandt, V., Bezard, E., et al. (2013). Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. *Ann. Neurol.* 74, 140–144. doi: 10.1002/ana.23881
- Feany, M. B., and Bender, W. W. (2000). A *Drosophila* model of Parkinson's disease. *Nature* 404, 394–398. doi: 10.1038/35006074
- Fernagut, P.-O., and Chesselet, M.-F. (2004). Alpha-synuclein and transgenic mouse models. *Neurobiol. Dis.* 17, 123–130. doi: 10.1016/j.nbd.2004.07.001
- Fett, M. E., Pils, A., Paquet, D., van Bebber, F., Haass, C., Tatzelt, J., et al. (2010). Parkin is protective against proteotoxic stress in a transgenic zebrafish model. *PLoS ONE* 5:e11783. doi: 10.1371/journal.pone.0011783
- Fleming, S. M., Zhu, C., Fernagut, P. O., Mehta, A., DiCarlo, C. D., Seaman, R. L., et al. (2004). Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. *Exp. Neurol.* 187, 418–429. doi: 10.1016/j.expneurol.2004.01.023
- Flinn, L., Mortiboys, H., Volkman, K., Köster, R. W., Ingham, P. W., and Bandmann, O. (2009). Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (*Danio rerio*). *Brain* 132, 1613–1623. doi: 10.1093/brain/awp108
- Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., et al. (2005). Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and -synuclein. *Proc. Natl. Acad. Sci. U.S.A.* 102, 3413–3418. doi: 10.1073/pnas.0409713102
- Funayama, M., Hasegawa, K., and Kowa, H. (2002). A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. *Ann. Neurol.* 51, 296–301. doi: 10.1002/ana.10113
- Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., and Lee, V. M.-Y. (2002). Neuronal alpha-synucleinopathy with severe movement disorder

- in mice expressing A53T human alpha-synuclein. *Neuron* 34, 521–533. doi: 10.1016/S0896-6273(02)00682-7
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., et al. (2003). Parkin-deficient Mice Exhibit Nigrostriatal Deficits but not Loss of Dopaminergic Neurons. *J. Biol. Chem.* 278, 43628–43635. doi: 10.1074/jbc.M308947200
- Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., et al. (2005). Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. *Neuron* 45, 489–496. doi: 10.1016/j.neuron.2005.01.041
- Gomez-Isla, T., Irizarry, M. C., Mariash, A., Cheung, B., Soto, O., Schrupp, S., et al. (2003). Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. *Neurobiol. Aging* 24, 245–258. doi: 10.1016/S0197-4580(02)00091-X
- Granado, N., Escobedo, I., O'Shea, E., Colado, M. I., and Moratalla, R. (2008a). Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. *Synapse* 62, 80–84. doi: 10.1002/syn.20466
- Granado, N., O'Shea, E., Bove, J., Vila, M., Colado, M. I., and Moratalla, R. (2008b). Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. *J. Neurochem.* 107, 1102–1112. doi: 10.1111/j.1471-4159.2008.05705.x
- Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., and Pallanck, L. J. (2003). Mitochondrial pathology and apoptotic muscle degeneration in *Drosophila* parkin mutants. *Proc. Natl. Acad. Sci. U.S.A.* 100, 4078–4083. doi: 10.1073/pnas.0737556100
- Haque, M. E., Mount, M. P., Safarpour, F., Abdel-Messih, E., Callaghan, S., Mazerolle, C., et al. (2012). Inactivation of Pink1 gene *in vivo* Sensitizes dopamine-producing neurons to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson Disease genes, parkin or DJ-1. *J. Biol. Chem.* 287, 23162–23170. doi: 10.1074/jbc.M112.346437
- Hinkle, K. M., Yue, M., Behrouz, B., Dächsel, J. C., Lincoln, S. J., Bowles, E. E., et al. (2012). LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. *Mol. Neurodegener.* 7:25. doi: 10.1186/1750-1326-7-25
- Hirth, F. (2010). *Drosophila melanogaster* in the study of human neurodegeneration. *CNS Neurol. Disord. Drug Targets* 9, 504–523. doi: 10.2174/187152710791556104
- Howard, C. D., Keefe, K. A., Garriss, P. A., and Daberkow, D. P. (2011). Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum. *J. Neurochem.* 118, 668–676. doi: 10.1111/j.1471-4159.2011.07342.x
- Itier, J. M., Ibáñez, P., Mena, M. A., Abbas, N., Cohen-Salmon, C., Bohme, G. A., et al. (2003). Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. *Hum. Mol. Genet.* 12, 2277–2291. doi: 10.1093/hmg/ddg239
- Iwatsubo, T. (2003). Aggregation of α -synuclein in the pathogenesis of Parkinson's disease. *J. Neurol.* 250, 1. doi: 10.1007/s00415-003-1303-x
- Jackson-Lewis, V., and Przedborski, S. (2007). Protocol for the MPTP mouse model of Parkinson's disease. *Nat. Protoc.* 2, 141–151. doi: 10.1038/nprot.2006.342
- Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., and Snyder, S. H. (1985). Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. *Proc. Natl. Acad. Sci. U.S.A.* 82, 2173–2177.
- Jellinger, K. A. (1991). Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. *Mol. Chem. Neuropathol.* 14, 153–197. doi: 10.1007/BF03159935
- Jeon, B. S., Jackson-Lewis, V., and Burke, R. E. (1995). 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. *Neurodegeneration* 4, 131–137. doi: 10.1006/neur.1995.0016
- Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegemann, J., Brunner, B., et al. (2010). Inhibition of mitochondrial fusion by α -synuclein is rescued by PINK1, Parkin and DJ-1. *EMBO J.* 29, 3571–3589. doi: 10.1038/emboj.2010.223
- Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., et al. (2013). α -Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? *Acta Neuropathol.* 125, 753–769. doi: 10.1007/s00401-013-1096-7
- Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., et al. (2005). Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. *Proc. Natl. Acad. Sci. U.S.A.* 102, 5215–5220. doi: 10.1073/pnas.0501282102
- Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., et al. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. *J. Neurosci.* 22, 2780–2791.
- Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tschertner, A., Martella, G., et al. (2007). Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. *Proc. Natl. Acad. Sci. U.S.A.* 104, 11441–11446. doi: 10.1073/pnas.0702717104
- Kitada, T., Tong, Y., Gautier, C. A., and Shen, J. (2009). Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. *J. Neurochem.* 111, 696–702. doi: 10.1111/j.1471-4159.2009.06350.x
- Klein, R. L., King, M. A., Hamby, M. E., and Meyer, E. M. (2002). Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. *Hum. Gene Ther.* 13, 605–612. doi: 10.1089/10430340252837206
- Koprich, J. B., Johnston, T. H., Reyes, M. G., Sun, X., and Brotchie, J. M. (2010). Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pat. *Mol. Neurodegener.* 5:43. doi: 10.1186/1750-1326-5-43
- Kowall, N. W., Hantraye, P., Brouillet, E., Beal, M. F., McKee, A. C., and Ferrante, R. J. (2000). MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. *Neuroreport* 11, 211–213. doi: 10.1097/00001756-200001170-00041
- Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat. Genet.* 18, 106–108. doi: 10.1038/ng0298-106
- Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., and Sulzer, D. (2002). Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. *J. Neurosci.* 22, 8951–8960.
- Lauwers, E., Bequé, D., Van Laere, K., Nuyts, J., Bormans, G., Mortelmans, L., et al. (2007). Non-invasive imaging of neuropathology in a rat model of α -synuclein overexpression. *Neurobiol. Aging* 28, 248–257. doi: 10.1016/j.neurobiolaging.2005.12.005
- Lauwers, E., Debyser, Z., Van Dorpe, J., De Strooper, B., Nuttin, B., and Baekelandt, V. (2003). Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. *Brain Pathol.* 13, 364–372. doi: 10.1111/j.1750-3639.2003.tb00035.x
- Lavara-Culebras, E., and Paricio, N. (2007). *Drosophila* DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. *Gene* 400, 158–165. doi: 10.1016/j.gene.2007.06.013
- Lazarou, M., Narendra, D. P., Jin, S. M., Tekle, E., Banerjee, S., and Youle, R. J. (2013). PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. *J. Cell Biol.* 200, 163–172. doi: 10.1083/jcb.201210111
- Lee, J.-Y., Kim, C., Kim, J., and Park, C. (2013). DJR-1.2 of *Caenorhabditis elegans* is induced by DAF-16 in the dauer state. *Gene* 524, 373–376. doi: 10.1016/j.gene.2013.04.032
- Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., et al. (2002). Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.* 99, 8968–8973. doi: 10.1073/pnas.132197599
- Li, J., Dani, J. A., and Le, W. (2009a). The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease. *Curr. Top. Med. Chem.* 9, 855–859. doi: 10.2174/156802609789378236
- Li, X., Tan, Y.-C., Poulou, S., Olanow, C. W., Huang, X.-Y., and Yue, Z. (2007). Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. *J. Neurochem.* 103, 238–247. doi: 10.1111/j.1471-4159.2007.04743.x
- Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., et al. (2009b). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. *Nat. Neurosci.* 12, 826–828. doi: 10.1038/nn.2349

- Lin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., et al. (2012). Conditional expression of Parkinson's disease-related mutant α -synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. *J. Neurosci.* 32, 9248–9264. doi: 10.1523/JNEUROSCI.1731-12.2012
- Liu, B., Traini, R., Killinger, B., Schneider, B., and Moszczynska, A. (2013). Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. *Exp. Neurol.* 247, 359–372. doi: 10.1016/j.expneurol.2013.01.001
- Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., et al. (2008). A *Drosophila* model for LRRK2-linked parkinsonism. *Proc. Natl. Acad. Sci. U.S.A.* 105, 2693–2698. doi: 10.1073/pnas.0708452105
- Lo Bianco, C., Ridet, J.-L., Schneider, B. L., Deglon, N., and Aebischer, P. (2002). α -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. *Proc. Natl. Acad. Sci. U.S.A.* 99, 10813–10818. doi: 10.1073/pnas.152339799
- Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., et al. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. *N. Engl. J. Med.* 342, 1560–1567. doi: 10.1056/NEJM200005253422103
- Lu, X.-H., Fleming, S. M., Meurers, B., Ackerson, L. C., Mortazavi, F., Lo, V., et al. (2009). Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase k-resistant α -synuclein. *J. Neurosci.* 29, 1962–1976. doi: 10.1523/JNEUROSCI.5351-08.2009
- Luthman, J., Fredriksson, A., Sundström, E., Jonsson, G., and Archer, T. (1989). Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. *Behav. Brain Res.* 33, 267–277. doi: 10.1016/S0166-4328(89)80121-4
- Manning-Boğ, A. B., Caudle, W. M., Perez, X. A., Reaney, S. H., Paletzki, R., Isla, M. Z., et al. (2007). Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. *Neurobiol. Dis.* 27, 141–150. doi: 10.1016/j.nbd.2007.03.014
- Maries, E., Dass, B., Collier, T. J., Kordower, J. H., and Steece-Collier, K. (2003). The role of α -synuclein in Parkinson's disease: insights from animal models. *Nat. Rev. Neurosci.* 4, 727–738. doi: 10.1038/nrn1199
- Marin, I. (2006). The Parkinson disease gene LRRK2: evolutionary and structural insights. *Mol. Biol. Evol.* 23, 2423–2433. doi: 10.1093/molbev/msl114
- Masliah, E. (2000). Dopaminergic loss and inclusion body formation in α -synuclein mice: implications for neurodegenerative disorders. *Science* 287, 1265–1269. doi: 10.1126/science.287.5456.1265
- Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., and Gallo, K. A. (2006). LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends Neurosci.* 29, 286–293. doi: 10.1016/j.tins.2006.03.006
- Matsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Picciano, M., LaFrancois, J., et al. (2001). Lack of nigral pathology in transgenic mice expressing human α -synuclein driven by the tyrosine hydroxylase promoter. *Neurobiol. Dis.* 8, 535–539. doi: 10.1006/nbdi.2001.0392
- McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., et al. (2002). Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. *Neurobiol. Dis.* 10, 119–127. doi: 10.1006/nbdi.2002.0507
- McFarland, N. R., Fan, Z., Xu, K., Schwarzschild, M. A., Feany, M. B., Hyman, B. T., et al. (2009). α -Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. *J. Neuropathol. Exp. Neurol.* 68, 515–524. doi: 10.1097/NEN.0b013e3181a24b53
- McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. *Nat. Rev. Neurosci.* 2, 589–594. doi: 10.1038/35086067
- Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., et al. (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. *Neurobiol. Dis.* 40, 503–517. doi: 10.1016/j.nbd.2010.07.010
- Menzies, F. M., Yenisseti, S. C., and Min, K. T. (2005). Roles of *Drosophila* DJ-1 in survival of dopaminergic neurons and oxidative stress. *Curr. Biol.* 15, 1578–1582. doi: 10.1016/j.cub.2005.07.036
- Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., and Lau, Y.-S. (2002). Lysosomal malfunction accompanies α -synuclein aggregation in a progressive mouse model of Parkinson's disease. *Brain Res.* 956, 156–165. doi: 10.1016/S0006-8993(02)03514-X
- Meulener, M., Whitworth, A. J., Armstrong-Gold, C. E., Rizzu, P., Heutink, P., Wes, P. D., et al. (2005). *Drosophila* DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. *Curr. Biol.* 15, 1572–1577. doi: 10.1016/j.cub.2005.07.064
- Milanesi, C., Sager, J. J., Bai, Q., Farrell, T. C., Cannon, J. R., Greenamyre, J. T., et al. (2012). Hypokinesia and reduced dopamine levels in zebrafish lacking β - and γ 1-synucleins. *J. Biol. Chem.* 287, 2971–2983. doi: 10.1074/jbc.M111.308312
- Miller, G. W. (2007). Paraquat: the red herring of Parkinson's Disease research. *Toxicol. Sci.* 100, 1–2. doi: 10.1093/toxsci/kfm223
- Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat. Genet.* 46, 989–993. doi: 10.1038/ng.3043
- Ng, C.-H., Mok, S. Z. S., Koh, C., Ouyang, X., Fivaz, M. L., Tan, E.-K., et al. (2009). Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in *Drosophila*. *J. Neurosci.* 29, 11257–11262. doi: 10.1523/JNEUROSCI.2375-09.2009
- Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado, M., Cabodevilla, F., Sánchez, B., et al. (2006). Increased sensitivity to MPTP in human α -synuclein A30P transgenic mice. *Neurobiol. Aging* 27, 848–856. doi: 10.1016/j.neurobiolaging.2005.04.010
- Nuber, S., Petrasch-Parwez, E., Winner, B., Winkler, J., von Hörsten, S., Schmidt, T., et al. (2008). Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. *J. Neurosci.* 28, 2471–2484. doi: 10.1523/JNEUROSCI.3040-07.2008
- O'Donnell, K. C., Lulla, A., Stahl, M. C., Wheat, N. D., Bronstein, J. M., and Sagasti, A. (2014). Axon degeneration and PGC-1 α -mediated protection in a zebrafish model of α -synuclein toxicity. *Dis. Model. Mech.* 7, 571–582. doi: 10.1242/dmm.013185
- Oliveras-Salv , M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D'Hooge, R., et al. (2013). rAAV2/7 vector-mediated overexpression of α -synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. *Mol. Neurodegener.* 8:44. doi: 10.1186/1750-1326-8-44
- Oueslati, A., Paleologou, K. E., Schneider, B. L., Aebischer, P., and Lashuel, H. A. (2012). Mimicking phosphorylation at serine 87 inhibits the aggregation of human α -synuclein and protects against its toxicity in a rat model of Parkinson's Disease. *J. Neurosci.* 32, 1536–1544. doi: 10.1523/JNEUROSCI.3784-11.2012
- Ovadia, A., Zhang, Z., and Gash, D. M. (1995). Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. *Neurobiol. Aging* 16, 931–937. doi: 10.1016/0197-4580(95)02012-8
- Pais n-Ru z, C., Jain, S., Evans, E. W., Gilks, W. P., Sim n, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44, 595–600. doi: 10.1016/j.neuron.2004.10.023
- Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., et al. (2004). Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice. *J. Biol. Chem.* 279, 18614–18622. doi: 10.1074/jbc.M401135200
- Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S., and Chung, J. (2005). *Drosophila* DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. *Gene* 361, 133–139. doi: 10.1016/j.gene.2005.06.040
- Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., et al. (2006). Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature* 441, 1157–1161. doi: 10.1038/nature04788
- Perez, F. A., and Palmiter, R. D. (2005). Parkin-deficient mice are not a robust model of parkinsonism. *Proc. Natl. Acad. Sci. U.S.A.* 102, 2174–2179. doi: 10.1073/pnas.0409598102
- Perez, R. G., and Hastings, T. G. (2004). Could a loss of α -synuclein function put dopaminergic neurons at risk? *J. Neurochem.* 89, 1318–1324. doi: 10.1111/j.1471-4159.2004.02423.x
- Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., and Feany, M. B. (2007). Aggregated α -synuclein mediates dopaminergic neurotoxicity in vivo. *J. Neurosci.* 27, 3338–3346. doi: 10.1523/JNEUROSCI.0285-07.2007

- Pesah, Y., Burgess, H., Middlebrooks, B., Ronningen, K., Prosser, J., Tirunagaru, V., et al. (2005). Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-Synuclein in *Drosophila*. *Genesis* 41, 154–159. doi: 10.1002/gene.20106
- Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., et al. (2004). *Drosophila* parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. *Development* 131, 2183–2194. doi: 10.1242/dev.01095
- Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276, 2045–2047. doi: 10.1126/science.276.5321.2045
- Poulin, J.-F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y. A., Cicchetti, F., and Awatramani, R. B. (2014). Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. *Cell Rep.* 9, 930–943. doi: 10.1016/j.celrep.2014.10.008
- Priyadarshini, M., Tuimala, J., Chen, Y. C., and Panula, P. (2013). A zebrafish model of PINK1 deficiency reveals key pathway dysfunction including HIF signaling. *Neurobiol. Dis.* 54, 127–138. doi: 10.1016/j.nbd.2013.02.002
- Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., et al. (2013). A novel α -synuclein missense mutation in Parkinson disease. *Neurology* 80, 1062–1064. doi: 10.1212/WNL.0b013e318282727ba
- Przedborski, S., Levivier, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastratial injection of 6-hydroxydopamine. *Neuroscience* 67, 631–647. doi: 10.1016/0306-4522(95)00066-R
- Quilty, M. C., King, A. E., Gai, W.-P., Pountney, D. L., West, A. K., Vickers, J. C., et al. (2006). Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. *Exp. Neurol.* 199, 249–256. doi: 10.1016/j.expneurol.2005.10.018
- Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., et al. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS ONE* 6:e18568. doi: 10.1371/journal.pone.0018568
- Ramsay, R. R., and Singer, T. P. (1986). Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. *J. Biol. Chem.* 261, 7585–7587.
- Riachi, N. J., Dietrich, W. D., and Harik, S. I. (1990). Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. *Brain Res.* 533, 6–14. doi: 10.1016/0006-8993(90)91788-1
- Richfield, E. K., Thiruchelvan, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., et al. (2002). Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. *Exp. Neurol.* 175, 35–48. doi: 10.1006/exnr.2002.7882
- Rodríguez-Oroz, M. C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., et al. (2009). Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. *Lancet Neurol.* 8, 1128–1139. doi: 10.1016/S1474-4422(09)70293-5
- Rousseaux, M. W. C., Marcogliese, P. C., Qu, D., Hewitt, S. J., Seang, S., Kim, R. H., et al. (2012). Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. *Proc. Natl. Acad. Sci. U.S.A.* 109, 15918–15923. doi: 10.1073/pnas.1205102109
- Sakaguchi-Nakashima, A., Meir, J. Y., Jin, Y., Matsumoto, K., and Hisamoto, N. (2007). LRK-1, a *C. elegans* PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. *Curr. Biol.* 17, 592–598. doi: 10.1016/j.cub.2007.01.074
- Sämann, J., Hegemann, J., von Gromoff, E., Eimer, S., Baumeister, R., and Schmidt, E. (2009). Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. *J. Biol. Chem.* 284, 16482–16491. doi: 10.1074/jbc.M808255200
- Sang, T.-K., Chang, H.-Y., Lawless, G. M., Ratnaparkhi, A., Mee, L., Ackerson, L. C., et al. (2007). A *Drosophila* model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. *J. Neurosci.* 27, 981–992. doi: 10.1523/JNEUROSCI.4810-06.2007
- Sauer, H., and Oertel, W. H. (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastratial terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. *Neuroscience* 59, 401–415. doi: 10.1016/0306-4522(94)90605-X
- Schmidt, N., and Ferger, B. (2001). Neurochemical findings in the MPTP model of Parkinson's disease. *J. Neural Transm.* 108, 1263–1282. doi: 10.1007/s007020100004
- Shendelman, S., Jonason, A., Martinat, C., Leete, T., and Abeliovich, A. (2004). DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. *PLoS Biol.* 2:e362. doi: 10.1371/journal.pbio.0020362
- Sheng, D., Qu, D., Kwok, K. H. H., Ng, S. S., Lim, A. Y. M., Aw, S. S., et al. (2010). Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. *PLoS Genet.* 6:e1000914. doi: 10.1371/journal.pgen.1000914
- Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., et al. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. *J. Neurosci.* 23, 10756–10764.
- Simola, N., Morelli, M., and Carta, A. R. (2007). The 6-hydroxydopamine model of Parkinson's disease. *Neurotox. Res.* 11, 151–167. doi: 10.1007/BF03033565
- Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302, 841. doi: 10.1126/science.1090278
- Springer, W., Hoppe, T., Schmidt, E., and Baumeister, R. (2005). A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. *Hum. Mol. Genet.* 14, 3407–3423. doi: 10.1093/hmg/ddi371
- Srivastava, P., and Panda, D. (2007). Rotenone inhibits mammalian cell proliferation by inhibiting microtubule assembly through tubulin binding. *FEBS J.* 274, 4788–4801. doi: 10.1111/j.1742-4658.2007.06004.x
- St Martin, J. L., Klucken, J., Outeiro, T. F., Nguyen, P., Keller-McGandy, C., Cantuti-Castelvetri, I., et al. (2007). Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. *J. Neurochem.* 100, 1449–1457. doi: 10.1111/j.1471-4159.2006.04310.x
- Talpad, D. J., Greene, J. G., Higgins, D. S., and Greenamyre, J. T. (2000). In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydorotenone. *J. Neurochem.* 75, 2611–2621. doi: 10.1046/j.1471-4159.2000.0752611.x
- Thiele, S. L., Warre, R., and Nash, J. E. (2012). Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. *J. Vis. Exp.* 60:3234. doi: 10.3791/3234
- Thiruchelvan, M. J., Powers, J. M., Cory-Slechta, D. A., and Richfield, E. K. (2004). Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. *Eur. J. Neurosci.* 19, 845–854. doi: 10.1111/j.0953-816X.2004.03139.x
- Thrash, B., Thiruchelvan, K., Ahuja, M., Suppiramaniam, V., and Dhanasekaran, M. (2009). Methamphetamine-induced neurotoxicity: the road to Parkinson's disease. *Pharmacol. Rep.* 61, 966–977. doi: 10.1016/S1734-1140(09)70158-6
- Thrash, B., Uthayathas, S., Karuppagounder, S. S., Suppiramaniam, V., and Dhanasekaran, M. (2007). Paraquat and Maneb induced neurotoxicity. *Proc. West. Pharmacol. Soc.* 50, 31–42.
- Tofaris, G. K., Garcia-Reitböck, P., Humby, T., Lambourne, S. L., O'Connell, M., Ghetti, B., et al. (2006). Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. *J. Neurosci.* 26, 3942–3950. doi: 10.1523/JNEUROSCI.4965-05.2006
- Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., et al. (2009). R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. *Proc. Natl. Acad. Sci. U. S. A.* 106, 14622–14627. doi: 10.1073/pnas.0906334106
- Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., et al. (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9879–9884. doi: 10.1073/pnas.1004676107
- Tsika, E., Kannan, M., Foo, C. S.-Y., Dikeman, D., Glauser, L., Gellhaar, S., et al. (2014). Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiol. Dis.* 71, 345–358. doi: 10.1016/j.nbd.2014.08.027
- Ungerstedt, U. (1968). 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. *Eur. J. Pharmacol.* 5, 107–110. doi: 10.1016/0014-2999(68)90164-7

- van der Putten, H., Wiederhold, K.-H., Probst, A., Barbieri, S., Mistl, C., Danner, S., et al. (2000). Neuropathology in mice expressing human alpha-synuclein. *J. Neurosci.* 20, 6021–6029. doi: 10.1371/journal.pone.0024834
- Van Rompuy, A.-S., Lobbastael, E., Van der Perren, A., Van den Haute, C., and Baekelandt, V. (2014). Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration. *J. Neuropathol. Exp. Neurol.* 73, 159–174. doi: 10.1097/NEN.0000000000000039
- Varastet, M., Riche, D., Maziere, M., and Hantraye, P. (1994). Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. *Neuroscience* 63, 47–56. doi: 10.1016/0306-4522(94)90006-X
- Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., et al. (2005). Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of -synuclein, Parkin, and DJ-1 in *Caenorhabditis elegans*. *J. Biol. Chem.* 280, 42655–42668. doi: 10.1074/jbc.M505910200
- Venderova, K., Kabbach, G., Abdel-Messih, E., Zhang, Y., Parks, R. J., Imai, Y., et al. (2009). Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a *Drosophila melanogaster* model of Parkinson's disease. *Hum. Mol. Genet.* 18, 4390–4404. doi: 10.1093/hmg/ddp394
- Von Coelln, R., Thomas, B., Savitt, J. M., Lim, K. L., Sasaki, M., Hess, E. J., et al. (2004). Loss of locus coeruleus neurons and reduced startle in parkin null mice. *Proc. Natl. Acad. Sci. U.S.A.* 101, 10744–10749. doi: 10.1073/pnas.0401297101
- Wagner, G. C., Seiden, L. S., and Schuster, C. R. (1979). Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. *Drug Alcohol Depend.* 4, 435–438. doi: 10.1016/0376-8716(79)90076-0
- Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., et al. (2008). Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. *Neurobiol. Aging* 29, 574–585. doi: 10.1016/j.neurobiolaging.2006.11.017
- Winklhofer, K. F., and Haass, C. (2010). Mitochondrial dysfunction in Parkinson's disease. *Biochim. Biophys. Acta* 1802, 29–44. doi: 10.1016/j.bbadis.2009.08.013
- Xiong, N., Huang, J., Zhang, Z., Zhang, Z., Xiong, J., Liu, X., et al. (2009). Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's Disease. *PLoS ONE* 4:e7878. doi: 10.1371/journal.pone.0007878
- Yamada, M., Iwatsubo, T., Mizuno, Y., and Mochizuki, H. (2004). Overexpression of a-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of a-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. *J. Neurochem.* 91, 451–461. doi: 10.1111/j.1471-4159.2004.02728.x
- Yamaguchi, H., and Shen, J. (2007). Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice. *Mol. Neurodegener.* 2:10. doi: 10.1186/1750-1326-2-10
- Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann. Neurol.* 55, 164–173. doi: 10.1002/ana.10795

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer Dr Ines Moreno-Gonzalez and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.

Copyright © 2016 Jagmag, Tripathi, Shukla, Maiti and Khurana. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.